Oscar Health (OSCR) traded higher as the market focused on the company’s scheduled first-quarter 2026 earnings release and its 8:00 a.m. ET conference call set for Wednesday, May 6, 2026. With results imminent, the stock’s move looks driven by event positioning and expectations for confirmation of profitability progress and membership-driven growth. (marketbeat.com)

Oscar has already set a bullish framework for 2026: total revenue guidance of $18.7–$19.0 billion and operating income (earnings from operations) guidance of $250–$450 million, alongside targets for lower medical loss ratio (82.4%–83.4%) and improved SG&A expense ratio (15.8%–16.3%). Traders are effectively betting that the Q1 print and commentary keep that full-year trajectory credible. (s27.q4cdn.com)

In late April, Oscar reaffirmed its full-year 2026 guidance and disclosed a board leadership change, naming Siddhartha Sankaran as independent chair effective June 4, 2026. While not a direct earnings catalyst, the reaffirmation reduced near-term guidance-risk heading into the Q1 report, which can amplify pre-earnings buying. (tradingview.com)

The next direction for OSCR likely hinges on whether Q1 numbers and the call commentary validate the full-year outlook—especially any discussion of medical cost trends (MLR), risk adjustment, and the pace of paid membership conversion as the year progresses. If results or guidance tone disappoint, the same event-driven positioning that’s lifting the stock could unwind quickly following the release and Q&A.